These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 35371436

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R, Rengarajan S, Budden JJ, Quinn CM, Kalra PA.
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: Analysis of French data from the PROKALE multinational European study].
    Rossignol P, investigateurs de PROKALEUniversité de Lorraine, Inserm, Centre d'Investigations Cliniques - Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France..
    Nephrol Ther; 2021 Oct; 17(6):422-427. PubMed ID: 33994135
    [Abstract] [Full Text] [Related]

  • 6. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW, Won YW, Yi JH, Kim HJ.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia.
    Gorriz JL, D'Marco L, Pastor-González A, Molina P, Gonzalez-Rico M, Puchades MJ, Sanchis I, Escudero V, Estañ N, de la Espriella R, Nuñez E, Pallardó L, Núñez J.
    Nephrol Dial Transplant; 2022 Feb 25; 37(3):522-530. PubMed ID: 33508124
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Epidemiology and risk factors for hyperkalaemia in heart failure.
    Grobbee DE, Filippatos G, Desai NR, Coats AJS, Pinto F, Rosano GMC, Cleland JGF, Kammerer J, de Arellano AR.
    ESC Heart Fail; 2024 Aug 25; 11(4):1821-1840. PubMed ID: 38439165
    [Abstract] [Full Text] [Related]

  • 13. The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland.
    Ward T, Brown T, Lewis RD, Kliess MK, de Arellano AR, Quinn CM.
    Pharmacoecon Open; 2022 Sep 25; 6(5):757-771. PubMed ID: 35925491
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.